Kalapa Clinic está compuesta por un equipo multidisciplinar de doctores, psicólogos e investigadores, unidos por la sincera opinión de que la Cannabis Sativa L tiene innumerables posibles usos terapeúticos . Apoyamos el derecho inalienable a decidir, tanto el paciente como el facultativo,a la hora de prescribir o realizar un seguimiento en tratamientos con cannabinoides.
“… conocido por afectar roles metabólicos vitales en los humanos, que varían desde el control de inflamaciones y tono vascular, hasta la iniciación de contracciones durante el parto. GLA ha sido encontrado de aliviar psoriasis, eczema atópica, y mastalgia, y también puede ser benéfico para disfunciones cardiovasculares, psiquiátricas e inmunológicas."
Existen numerosos trabajos que demuestran interacción entre ambos sistemas endógenos, que pueden actuar de forma sinérgica para potenciar mecanismos inhibidores. Desde el punto de vista farmacológico, la utilidad de emplear dos sistemas que actúan de la misma manera debe ser la de poder reducir la dosis de uno de ellos, con el fin de disminuir los efectos secundarios.
The FDA relies on applicants and scientific investigators to conduct research. Our role, as outlined in the Federal Food, Drug, and Cosmetic Act, is to review data submitted to the FDA in a marketing application to determine whether a proposed drug product meets the statutory standards for approval. Additional information concerning research on the medical use of marijuana is available from the National Institutes of Health, particularly the National Cancer Institute (NCI) and NIDA.
In 2019, the European Food Safety Authority (EFSA) announced that CBD and other cannabinoids would be classified as "novel foods", meaning that CBD products would require authorization under the EU Novel Food Regulation stating: because "this product was not used as a food or food ingredient before 15 May 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required." The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019. If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021.
Disclaimer: While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Amazon.com assumes no liability for inaccuracies or misstatements about products.